Arquivos do dia: Abril 5, 2022
Estratégia da OMS para preparo, prontidão e plano de resposta para o fim da emergência global de Covid-19 em 2022.
5 Abr, 2022 | 12:30h
Comentário no Twitter (fio – clique para saber mais)
"WHO is releasing updated Strategic Preparedness, Readiness & Response Plan for #COVID19. This is our 3rd strategic plan for COVID-19, & it could & should be our last. It lays out 3️⃣ possible scenarios for how the pandemic could evolve this year"-@DrTedros https://t.co/ryb0QdlTqG
— World Health Organization (WHO) (@WHO) March 30, 2022
#ACC22 | Diretriz 2022 AHA/ACC/HFSA para tratamento de insuficiência cardíaca.
5 Abr, 2022 | 12:28hDiretriz ACC: Heart Failure
Resumo executivo: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Comunicado de imprensa: ACC, AHA, HFSA Issue Heart Failure Guideline – American Heart Association
Principais perspectivas: 2022 AHA/ACC/HFSA Heart Failure Guideline
Download de série de slides: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Comentário no Twitter
New ACC/AHA/HFSA clinical guideline provides patient-centric recommendations for clinicians to prevent, diagnose, and manage patients with #HeartFailure.
Get the details in #JACC: https://t.co/zfbKMXxDNf#ClinicalGuidelines #HFrEF #CardioTwitter pic.twitter.com/hrvTj4TQUm
— JACC Journals (@JACCJournals) April 1, 2022
#ACC22 – Estudo randomizado | Ácido tranexâmico reduz o risco de sangramento em pacientes submetidos a cirurgia não cardíaca.
5 Abr, 2022 | 12:26hTranexamic Acid in Patients Undergoing Noncardiac Surgery – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comentários:
POISE-3: Tranexamic Acid Stems Bleeding During Noncardiac Surgery – TCTMD
Comentários no Twitter
HOT OFF THE PRESS:POISE-3 Tranexamic Acid
Incidence of composite bleeding outcome significantly lower with tranexamic acid vs placebo; between-group difference in composite CV outcome was small, but noninferiority of tranexamic acid was not established.https://t.co/FyuBliD0Mr— Steven Cohn, MD (@preopconsult) April 2, 2022
Among patients undergoing noncardiac surgery, the incidence of the composite bleeding outcome was significantly lower with tranexamic acid than with placebo. #ACC22 https://t.co/cYIQhE7YCD pic.twitter.com/l0QKgpEqnG
— NEJM (@NEJM) April 2, 2022
POISE-3 trial results showed a single dose of tranexamic acid before & after surgery significantly ⬇️ severe bleeding risk in pts undergoing noncardiac surgery compared w/ placebo. Findings could have global 🌏 impact, researchers said. https://t.co/LratgyadtE #ACC22 #cvSurg pic.twitter.com/HXlcp6bb0M
— American College of Cardiology (@ACCinTouch) April 2, 2022
#ACC22 – Estudo randomizado | Tratamento para hipertensão crônica leve durante a gestação está associada com melhores desfechos gestacionais do que a estratégia de tratamento reservado somente para hipertensão grave.
5 Abr, 2022 | 12:25hTreatment for Mild Chronic Hypertension during Pregnancy – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comentários:
Treating chronic hypertension in early pregnancy benefits parents, babies – NIH News Releases
CHAP: Better Blood Pressure Control, Better Pregnancy Outcomes – TCTMD
Comentário no Twitter
In pregnant women with mild chronic hypertension, targeting a blood pressure of < 140/90 mm Hg was associated with better pregnancy outcomes than a strategy of reserving treatment only for severe hypertension. #ACC22 https://t.co/fDrqa8uQiO pic.twitter.com/9KvogjnKcc
— NEJM (@NEJM) April 2, 2022
#ACC22 – Estudo randomizado | Entre pacientes ambulatoriais com insuficiência cardíaca, uma intervenção dietética para reduzir a ingestão de sódio não reduziu os eventos clínicos.
5 Abr, 2022 | 12:23hReduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial – The Lancet (necessário cadastro gratuito)
Comentários:
SODIUM-HF: No Impact of Dietary Salt Restriction on Death or Hospitalization – TCTMD
Comentário no Twitter
Nutritional counseling/strictly limiting sodium intake didn’t significantly reduce MACE in #HeartFailure patients in 6️⃣ countries, but did modestly improve QOL according to results of SODIUM-HF trial presented at #ACC22. https://t.co/ESjiy6g8a7 #ACCIntl #cvPrev #CardioNutrition pic.twitter.com/CjK6CfWNXg
— American College of Cardiology (@ACCinTouch) April 2, 2022
Pesquisadores geram a primeira sequência do genoma humano completa e sem falhas.
5 Abr, 2022 | 12:21hComunicado de imprensa: Researchers generate the first complete, gapless sequence of a human genome – NIH News Releases
Estudo original: The complete sequence of a human genome – Science
Comentários:
Scientists sequence the complete human genome for the first time – CNN
First complete gap-free human genome sequence published – The Guardian
Scientists finally finish decoding entire human genome – Associated Press
Segurança, tolerabilidade e cinética viral durante o desafio do SARS-CoV-2 humano em adultos jovens (infectando indivíduos deliberadamente em ambiente controlado).
5 Abr, 2022 | 12:20hComentários:
Understanding COVID-19 through human challenge models – Nature Medicine
First human challenge study of Covid-19 yields valuable insights about how we get sick – CNN
First Human Challenge Trial Shows How COVID-19 Strikes – HealthDay
Conteúdos relacionados:
Scientists deliberately gave people COVID — here’s what they learnt.
World’s first coronavirus “Human Challenge” study receives ethics approval in the UK (vários textos sobre o assunto)
Comentário no Twitter
In the first #SARSCoV2 challenge study in humans, healthy adults were intranasally inoculated with virus and monitored for productive infection, symptoms, virus kinetics, antibody response and safety in a controlled setting @ChrisChiuLab #COVID19 https://t.co/b3H2ftaSFf
— Nature Medicine (@NatureMedicine) March 31, 2022
Estudo randomizado | Dose maior de primaquina é mais efetiva na prevenção de recorrência de malária por Plasmodium vivax em comparação com a dose padrão.
5 Abr, 2022 | 12:18h
Comentários no Twitter
To prevent relapse of Plasmodium vivax malaria, primaquine at a total dose of 7.0 mg per kilogram had higher efficacy than a total dose of 3.5 mg per kilogram. https://t.co/qIu27ruhKP pic.twitter.com/HdTNhqB0J1
— NEJM (@NEJM) April 1, 2022
In most of the Americas, recommended primaquine-based therapy for P. vivax malaria has moderate efficacy for preventing relapse. Whether higher-dose primaquine might reduce recurrence is unknown. New research findings are summarized in a short video. https://t.co/aFt9gNGg0m pic.twitter.com/oiAkLMgPIJ
— NEJM (@NEJM) April 2, 2022
Estudo randomizado e efetividade comparativa | 3 testes domiciliares de acuidade visual validados por meio da comparação com as medidas de acuidade visual feitas em consultório, apoiando seu uso potencial na teleoftalmologia.
5 Abr, 2022 | 12:16hValidation of Home Visual Acuity Tests for Telehealth in the COVID-19 Era – JAMA Ophthalmology (gratuito por tempo limitado)
Comentários:
Valid but Undervalued – JAMA Ophthalmology (gratuito por tempo limitado)
At-Home Visual Acuity Tests Valid Versus In-Office Testing – HealthDay
Dois novos estudos mostram que a vacinação forneceu proteção adicional após infecção por Covid-19.
5 Abr, 2022 | 12:14hComentários:
Vaccines offer substantial extra protection after COVID-19 infection – CIDRAP
Had COVID? Getting Vaccine Boosts Resilience Even More, Studies Show – HealthDay
Conteúdos relacionados:
Comentário no Twitter fio – clique para saber)
THREAD | New studies in @TheLancetInfDis confirm #COVID19 vaccines provide extra protection for those with immunity from previous infection, especially against severe disease ⤵️
(Cases of reinfection from omicron variants not included)
— The Lancet (@TheLancet) April 1, 2022